eligibility_summary
Inclusion: Adults ≥18 with relapsing MS (2017), eligible for anti‑CD20, Dutch/English proficient, consented, EDSS ≤6.5. Exclusion: hypersensitivity to OCR/RTX/gadolinium/steroids, PPMS/non‑active SPMS, chronic infections (TB, VZV, HBV/HCV, HIV), IBD, psych/cardiac/cancer contraindications, cytopenias or liver/renal/IgG abnormalities, pregnancy/no contraception, severe infusion reaction, recent steroids, disallowed prior/concurrent immunosuppression, other trials, substance abuse, MRI contraindications/refusal.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 randomized, double-blind non-inferiority trial in relapsing MS comparing rituximab vs ocrelizumab. Interventions: Rituximab (MabThera/Truxima/Ruxience/Rixathon), a chimeric IgG1 anti-CD20 monoclonal antibody, comparator Ocrelizumab, a humanized IgG1 anti-CD20 monoclonal antibody. Mechanism (both): bind CD20 on pre-B and mature B lymphocytes and deplete these cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis. Targeted cells/pathways: CD20+ B-cell compartments implicated in MS, reducing antigen presentation to T cells, costimulation and proinflammatory cytokines (e.g., IL-6, TNF), dampening B–T cell interactions and intrathecal inflammation, plasma cells and hematopoietic stem cells (CD20−) are largely spared.